EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische Studie

Comparative Effectiveness of Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis: A Propensity-Matched Cohort Analysis

Gursimran S Kochhar iD, Himsikhar Khataniar, Jana G Hashash iD, Fjona Tabaku, Miguel Regueiro iD, Francis A Farraye, Aakash Desai iD

Inflammatory Bowel Diseases · 07.07.2025 · 31 (7) · 1868-1875

DOI: 10.1093/ibd/izae251 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 30.10.2024. Verfasst von Gursimran S Kochhar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology & Nutrition, Allegheny Health Network, Pittsburgh, PA, USA. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Antibodies, Monoclonal, Humanized, Gastrointestinal Agents, Oxadiazoles. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

There is limited real-world evidence comparing the effectiveness of ozanimod to vedolizumab as first-line advanced therapies in patients with ulcerative colitis (UC).

Methods

We conducted a retrospective cohort study using TriNetX, a multi-institutional US database in adults with UC who were initiated on ozanimod compared to vedolizumab between January 1, 2021 and 22 June, 2024. The primary outcome was to compare the risk of a composite outcome of corticosteroid use, colectomy, or change to another advanced therapy between the 2 cohorts within 12 months. 1:1 propensity score matching (PSM) was performed for demographics, comorbid conditions, disease extent, laboratory parameters, and previous corticosteroid use. The risk was expressed as an adjusted odds ratio (aOR) with 95% CIs.

Results

We identified 222 patients in the ozanimod cohort (mean age 41.2 ± 15.7, 46.3% male sex, 68% White, and 22.5% ulcerative proctitis), and 4145 patients in the vedolizumab cohort (mean age 47.4 ± 18.3, 45.2% male sex, 69.7% White, and 17.2% ulcerative proctitis). After PSM, there was no significant difference in the risk of the composite outcome (aOR 0.92, 95% CI, 0.63-1.36) and corticosteroid use (aOR 0.80, 95% CI, 0.53-1.18) between the 2 cohorts within 12 months. There was a higher risk of change in therapy in the ozanimod cohort (aOR 1.95, 95% CI, 1.09-3.49) compared to the vedolizumab cohort. Colectomy rates were low in both cohorts (<0.04%).

Conclusions

Our real-world study showed that ozanimod use is associated with similar corticosteroid use but higher odds of a change in therapy compared to vedolizumab when used as first-line therapy in patients with UC. Further prospective studies are needed to understand long-term outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeAntibodies, Monoclonal, HumanizedGastrointestinal AgentsOxadiazolesHumansMaleFemaleAdultRetrospective StudiesMiddle AgedPropensity ScoreTreatment OutcomeColectomyAdrenal Cortex HormonesIndans

Stichwörter der Autor:innen

comparative effectivenessozanimodulcerative colitisvedolizumab

Substanzen

vedolizumabAntibodies, Monoclonal, HumanizedGastrointestinal AgentsozanimodOxadiazolesAdrenal Cortex HormonesIndans

Autor:innen und Institutionen

  • Division of Gastroenterology, Hepatology & Nutrition, Allegheny Health Network, Pittsburgh, PA, USA.
  • Department of Internal Medicine, Allegheny Health Network, Pittsburgh, PA, USA.
  • Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA.
  • Division of Gastroenterology and Hepatology, Cleveland Clinic Foundation, Cleveland, OH, USA.

ORCID-Profile: Gursimran S Kochhar, Jana G Hashash, Miguel Regueiro, Aakash Desai

Zitieren

APA

Kochhar, G. S., Khataniar, H., Hashash, J. G., Tabaku, F., Regueiro, M., Farraye, F. A., & Desai, A. (2025). Comparative Effectiveness of Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis: A Propensity-Matched Cohort Analysis. Inflammatory Bowel Diseases, 31(7), 1868-1875. https://doi.org/10.1093/ibd/izae251

Vancouver

Kochhar GS, Khataniar H, Hashash JG, Tabaku F, Regueiro M, Farraye FA, et al. Comparative Effectiveness of Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis: A Propensity-Matched Cohort Analysis. Inflammatory Bowel Diseases. 2025;31(7):1868-1875. doi:10.1093/ibd/izae251

BibTeX
@article{Kochhar2025,
  author = {Kochhar, Gursimran S and Khataniar, Himsikhar and Hashash, Jana G and Tabaku, Fjona and Regueiro, Miguel and Farraye, Francis A and Desai, Aakash},
  title = {Comparative Effectiveness of Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis: A Propensity-Matched Cohort Analysis},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  volume = {31},
  number = {7},
  pages = {1868--1875},
  doi = {10.1093/ibd/izae251}
}
Kostenlos starten →